Cargando…
Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study
BACKGROUND: The most frequent cause of hyperthyroidism is Graves' disease (GD). Orbitopathy is the most prevalent and recognizable extrathyroidal manifestation of Graves' disease with unrevealed pathogenesis. Interleukin 29 (IL-29) is a relatively newly discovered inflammatory cytokine. Th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368201/ https://www.ncbi.nlm.nih.gov/pubmed/32694926 http://dx.doi.org/10.1155/2020/4748612 |
_version_ | 1783560568464998400 |
---|---|
author | Falkowski, Bogusz Szczepanek-Parulska, Ewelina Sawicka-Gutaj, Nadia Krygier, Aleksandra Ruchala, Marek |
author_facet | Falkowski, Bogusz Szczepanek-Parulska, Ewelina Sawicka-Gutaj, Nadia Krygier, Aleksandra Ruchala, Marek |
author_sort | Falkowski, Bogusz |
collection | PubMed |
description | BACKGROUND: The most frequent cause of hyperthyroidism is Graves' disease (GD). Orbitopathy is the most prevalent and recognizable extrathyroidal manifestation of Graves' disease with unrevealed pathogenesis. Interleukin 29 (IL-29) is a relatively newly discovered inflammatory cytokine. Thus, the aim of this study was to evaluate the relationship between IL-29 and Graves' orbitopathy (GO) in euthyroid patients. METHODS: Thirty-one euthyroid patients with Graves' disease and with active GO [clinical activity score (CAS) ≥ 3/7], seventeen euthyroid patients with GD but without GO, and seventy-two healthy control subjects (CS) matched for age and gender were enrolled in the study. The following parameters were evaluated in every participant: thyroid-related hormones and autoantibodies and inflammatory markers (white blood cells, hsCRP). ELISA assay was applied to measure the concentration of IL-29. RESULTS: We found higher level of IL-29 in GO group in comparison with CS [165 (133-747) vs. 62 (62-217) pg/mL, p < 0.001]. Furthermore, participants in the subgroup with GD with GO as compared with GD without GO had higher concentration of IL-29 [165 (133-747) vs. 62 (62-558) pg/mL, p = 0.031]. The ROC analysis for IL-29 revealed IL-29 cut-off of 105 pg/mL (sensitivity 1.000 and specificity 0.597) as the best value significantly indicating the presence of GO in GD [area under the ROC curve (AUC): 0.739, 95% confidence interval (CI): 0.646-0.833, p < 0.001]. CONCLUSIONS: The present study revealed for the first time an elevated level of IL-29 in the serum of patients with GD and GO that might suggest its involvement in the pathogenesis of GD ocular complications. |
format | Online Article Text |
id | pubmed-7368201 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-73682012020-07-20 Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study Falkowski, Bogusz Szczepanek-Parulska, Ewelina Sawicka-Gutaj, Nadia Krygier, Aleksandra Ruchala, Marek Mediators Inflamm Research Article BACKGROUND: The most frequent cause of hyperthyroidism is Graves' disease (GD). Orbitopathy is the most prevalent and recognizable extrathyroidal manifestation of Graves' disease with unrevealed pathogenesis. Interleukin 29 (IL-29) is a relatively newly discovered inflammatory cytokine. Thus, the aim of this study was to evaluate the relationship between IL-29 and Graves' orbitopathy (GO) in euthyroid patients. METHODS: Thirty-one euthyroid patients with Graves' disease and with active GO [clinical activity score (CAS) ≥ 3/7], seventeen euthyroid patients with GD but without GO, and seventy-two healthy control subjects (CS) matched for age and gender were enrolled in the study. The following parameters were evaluated in every participant: thyroid-related hormones and autoantibodies and inflammatory markers (white blood cells, hsCRP). ELISA assay was applied to measure the concentration of IL-29. RESULTS: We found higher level of IL-29 in GO group in comparison with CS [165 (133-747) vs. 62 (62-217) pg/mL, p < 0.001]. Furthermore, participants in the subgroup with GD with GO as compared with GD without GO had higher concentration of IL-29 [165 (133-747) vs. 62 (62-558) pg/mL, p = 0.031]. The ROC analysis for IL-29 revealed IL-29 cut-off of 105 pg/mL (sensitivity 1.000 and specificity 0.597) as the best value significantly indicating the presence of GO in GD [area under the ROC curve (AUC): 0.739, 95% confidence interval (CI): 0.646-0.833, p < 0.001]. CONCLUSIONS: The present study revealed for the first time an elevated level of IL-29 in the serum of patients with GD and GO that might suggest its involvement in the pathogenesis of GD ocular complications. Hindawi 2020-07-09 /pmc/articles/PMC7368201/ /pubmed/32694926 http://dx.doi.org/10.1155/2020/4748612 Text en Copyright © 2020 Bogusz Falkowski et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Falkowski, Bogusz Szczepanek-Parulska, Ewelina Sawicka-Gutaj, Nadia Krygier, Aleksandra Ruchala, Marek Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study |
title | Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study |
title_full | Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study |
title_fullStr | Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study |
title_full_unstemmed | Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study |
title_short | Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study |
title_sort | evaluation of il-29 in euthyroid patients with graves' orbitopathy: a preliminary study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368201/ https://www.ncbi.nlm.nih.gov/pubmed/32694926 http://dx.doi.org/10.1155/2020/4748612 |
work_keys_str_mv | AT falkowskibogusz evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT szczepanekparulskaewelina evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT sawickagutajnadia evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT krygieraleksandra evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT ruchalamarek evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy |